Discovery and characterization of a novel potent, selective and orally active inhibitor for mammalian ELOVL6

Ken Shimamura, Akira Nagumo, Yasuhisa Miyamoto, Hidefumi Kitazawa, Maki Kanesaka, Ryo Yoshimoto, Katsumi Aragane, Naomi Morita, Tomoyuki Ohe, Toshiyuki Takahashi, Tsuyoshi Nagase, Nagaaki Sato, Shigeru Tokita

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The elongase of long chain fatty acids family 6 (ELOVL6) is a rate-limiting enzyme for the elongation of saturated and monounsaturated long chain fatty acids. ELOVL6 is abundantly expressed in lipogenic tissues such as liver, and its mRNA expression is up-regulated in obese model animals. ELOVL6 deficient mice are protected from high-fat-diet-induced insulin resistance, suggesting that ELOVL6 might be a new therapeutic target for diabetes. We previously identified an indoledione compound, Compound A, as the first inhibitor for mammalian ELOVL6. In this study, we discovered a novel compound, Compound B, and characterized its biochemical and pharmacological properties. Compound B has a more appropriate profile for use as a pharmacological tool compared to Compound A. Chronic treatment with Compound B in model animals, diet-induced obesity (DIO) and KKAy mice, showed significant reduction in hepatic fatty acid composition, suggesting that it effectively inhibits ELOVL6 activity in the liver. However, no improvement in insulin resistance by ELOVL6 inhibition was found in these model animals. Further studies need to address the impact of ELOVL6 inhibition on pharmacological abnormalities in several model animals. This is the first report on pharmacology data from chronic studies using a selective ELOVL6 inhibitor. Compound B appears to be a useful tool to further understand the physiological roles of ELOVL6 and to evaluate the therapeutic potential of ELOVL6 inhibitors.

Original languageEnglish
Pages (from-to)34-41
Number of pages8
JournalEuropean Journal of Pharmacology
Volume630
Issue number1-3
DOIs
Publication statusPublished - 2010 Mar
Externally publishedYes

Fingerprint

Animal Models
Pharmacology
Fatty Acids
Insulin Resistance
Liver
High Fat Diet
Obesity
Diet
Messenger RNA
Enzymes
Therapeutics

Keywords

  • Diabetes
  • Elovl
  • Inhibitor

ASJC Scopus subject areas

  • Pharmacology

Cite this

Shimamura, K., Nagumo, A., Miyamoto, Y., Kitazawa, H., Kanesaka, M., Yoshimoto, R., ... Tokita, S. (2010). Discovery and characterization of a novel potent, selective and orally active inhibitor for mammalian ELOVL6. European Journal of Pharmacology, 630(1-3), 34-41. https://doi.org/10.1016/j.ejphar.2009.12.033

Discovery and characterization of a novel potent, selective and orally active inhibitor for mammalian ELOVL6. / Shimamura, Ken; Nagumo, Akira; Miyamoto, Yasuhisa; Kitazawa, Hidefumi; Kanesaka, Maki; Yoshimoto, Ryo; Aragane, Katsumi; Morita, Naomi; Ohe, Tomoyuki; Takahashi, Toshiyuki; Nagase, Tsuyoshi; Sato, Nagaaki; Tokita, Shigeru.

In: European Journal of Pharmacology, Vol. 630, No. 1-3, 03.2010, p. 34-41.

Research output: Contribution to journalArticle

Shimamura, K, Nagumo, A, Miyamoto, Y, Kitazawa, H, Kanesaka, M, Yoshimoto, R, Aragane, K, Morita, N, Ohe, T, Takahashi, T, Nagase, T, Sato, N & Tokita, S 2010, 'Discovery and characterization of a novel potent, selective and orally active inhibitor for mammalian ELOVL6', European Journal of Pharmacology, vol. 630, no. 1-3, pp. 34-41. https://doi.org/10.1016/j.ejphar.2009.12.033
Shimamura, Ken ; Nagumo, Akira ; Miyamoto, Yasuhisa ; Kitazawa, Hidefumi ; Kanesaka, Maki ; Yoshimoto, Ryo ; Aragane, Katsumi ; Morita, Naomi ; Ohe, Tomoyuki ; Takahashi, Toshiyuki ; Nagase, Tsuyoshi ; Sato, Nagaaki ; Tokita, Shigeru. / Discovery and characterization of a novel potent, selective and orally active inhibitor for mammalian ELOVL6. In: European Journal of Pharmacology. 2010 ; Vol. 630, No. 1-3. pp. 34-41.
@article{4da61eab1a9344c79fe218e272a006d3,
title = "Discovery and characterization of a novel potent, selective and orally active inhibitor for mammalian ELOVL6",
abstract = "The elongase of long chain fatty acids family 6 (ELOVL6) is a rate-limiting enzyme for the elongation of saturated and monounsaturated long chain fatty acids. ELOVL6 is abundantly expressed in lipogenic tissues such as liver, and its mRNA expression is up-regulated in obese model animals. ELOVL6 deficient mice are protected from high-fat-diet-induced insulin resistance, suggesting that ELOVL6 might be a new therapeutic target for diabetes. We previously identified an indoledione compound, Compound A, as the first inhibitor for mammalian ELOVL6. In this study, we discovered a novel compound, Compound B, and characterized its biochemical and pharmacological properties. Compound B has a more appropriate profile for use as a pharmacological tool compared to Compound A. Chronic treatment with Compound B in model animals, diet-induced obesity (DIO) and KKAy mice, showed significant reduction in hepatic fatty acid composition, suggesting that it effectively inhibits ELOVL6 activity in the liver. However, no improvement in insulin resistance by ELOVL6 inhibition was found in these model animals. Further studies need to address the impact of ELOVL6 inhibition on pharmacological abnormalities in several model animals. This is the first report on pharmacology data from chronic studies using a selective ELOVL6 inhibitor. Compound B appears to be a useful tool to further understand the physiological roles of ELOVL6 and to evaluate the therapeutic potential of ELOVL6 inhibitors.",
keywords = "Diabetes, Elovl, Inhibitor",
author = "Ken Shimamura and Akira Nagumo and Yasuhisa Miyamoto and Hidefumi Kitazawa and Maki Kanesaka and Ryo Yoshimoto and Katsumi Aragane and Naomi Morita and Tomoyuki Ohe and Toshiyuki Takahashi and Tsuyoshi Nagase and Nagaaki Sato and Shigeru Tokita",
year = "2010",
month = "3",
doi = "10.1016/j.ejphar.2009.12.033",
language = "English",
volume = "630",
pages = "34--41",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "1-3",

}

TY - JOUR

T1 - Discovery and characterization of a novel potent, selective and orally active inhibitor for mammalian ELOVL6

AU - Shimamura, Ken

AU - Nagumo, Akira

AU - Miyamoto, Yasuhisa

AU - Kitazawa, Hidefumi

AU - Kanesaka, Maki

AU - Yoshimoto, Ryo

AU - Aragane, Katsumi

AU - Morita, Naomi

AU - Ohe, Tomoyuki

AU - Takahashi, Toshiyuki

AU - Nagase, Tsuyoshi

AU - Sato, Nagaaki

AU - Tokita, Shigeru

PY - 2010/3

Y1 - 2010/3

N2 - The elongase of long chain fatty acids family 6 (ELOVL6) is a rate-limiting enzyme for the elongation of saturated and monounsaturated long chain fatty acids. ELOVL6 is abundantly expressed in lipogenic tissues such as liver, and its mRNA expression is up-regulated in obese model animals. ELOVL6 deficient mice are protected from high-fat-diet-induced insulin resistance, suggesting that ELOVL6 might be a new therapeutic target for diabetes. We previously identified an indoledione compound, Compound A, as the first inhibitor for mammalian ELOVL6. In this study, we discovered a novel compound, Compound B, and characterized its biochemical and pharmacological properties. Compound B has a more appropriate profile for use as a pharmacological tool compared to Compound A. Chronic treatment with Compound B in model animals, diet-induced obesity (DIO) and KKAy mice, showed significant reduction in hepatic fatty acid composition, suggesting that it effectively inhibits ELOVL6 activity in the liver. However, no improvement in insulin resistance by ELOVL6 inhibition was found in these model animals. Further studies need to address the impact of ELOVL6 inhibition on pharmacological abnormalities in several model animals. This is the first report on pharmacology data from chronic studies using a selective ELOVL6 inhibitor. Compound B appears to be a useful tool to further understand the physiological roles of ELOVL6 and to evaluate the therapeutic potential of ELOVL6 inhibitors.

AB - The elongase of long chain fatty acids family 6 (ELOVL6) is a rate-limiting enzyme for the elongation of saturated and monounsaturated long chain fatty acids. ELOVL6 is abundantly expressed in lipogenic tissues such as liver, and its mRNA expression is up-regulated in obese model animals. ELOVL6 deficient mice are protected from high-fat-diet-induced insulin resistance, suggesting that ELOVL6 might be a new therapeutic target for diabetes. We previously identified an indoledione compound, Compound A, as the first inhibitor for mammalian ELOVL6. In this study, we discovered a novel compound, Compound B, and characterized its biochemical and pharmacological properties. Compound B has a more appropriate profile for use as a pharmacological tool compared to Compound A. Chronic treatment with Compound B in model animals, diet-induced obesity (DIO) and KKAy mice, showed significant reduction in hepatic fatty acid composition, suggesting that it effectively inhibits ELOVL6 activity in the liver. However, no improvement in insulin resistance by ELOVL6 inhibition was found in these model animals. Further studies need to address the impact of ELOVL6 inhibition on pharmacological abnormalities in several model animals. This is the first report on pharmacology data from chronic studies using a selective ELOVL6 inhibitor. Compound B appears to be a useful tool to further understand the physiological roles of ELOVL6 and to evaluate the therapeutic potential of ELOVL6 inhibitors.

KW - Diabetes

KW - Elovl

KW - Inhibitor

UR - http://www.scopus.com/inward/record.url?scp=77649192401&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77649192401&partnerID=8YFLogxK

U2 - 10.1016/j.ejphar.2009.12.033

DO - 10.1016/j.ejphar.2009.12.033

M3 - Article

VL - 630

SP - 34

EP - 41

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 1-3

ER -